Telaprevir for Previously Treated Chronic HCV Infection

2010719 citationsJournal Articlebronze Open Access

Authors

John G. McHutchison · Duke Medical Center

Michael P. Manns · Medizinische Hochschule Hannover

Andrew J. Muir · Duke Medical Center

Norah A. Terrault

Ira M. Jacobson · Cornell University

Nezam H. Afdhal · Hadassah Medical Center

E. Jenny Heathcote · University of Toronto

Abstract

In HCV-infected patients in whom initial peginterferon alfa and ribavirin treatment failed, retreatment with telaprevir in combination with peginterferon alfa-2a and ribavirin was more effective than retreatment with peginterferon alfa-2a and ribavirin alone. (ClinicalTrials.gov number, NCT00420784.)

Topics & Keywords

Hepatitis C virus research HIV/AIDS drug development and treatment Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 362, Issue 14, pp. 1292-1303

DOI: 10.1056/nejmoa0908014

Field-Weighted Citation Impact: 70.39